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It is our hope that this document will serve several useful
purposes. Our primary goal is to improve patient care. We
hope to accomplish this, in the short term, by helping
clinicians know and better understand the evidence (or lack
of evidence) that determines current practice. By providing
comprehensive evidence-based recommendations, this guide-
line will also help define areas where evidence is lacking and
research is needed. Helping to define a research agenda is an
often neglected, but very important, function of clinical
practice guideline development.
We used the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) system to rate the
strength of evidence and the strength of recommendations. In
all, there were only 2 (5.4%) recommendations in this guideline
for which the overall quality of evidence was graded ‘A,’ whereas
9 (24.3%) were graded ‘B,’ 14 (37.8%) were graded ‘C,’ and 12
(32.4%) were graded ‘D.’ Although there are reasons other than
quality of evidence to make a grade 1 or 2 recommendation, in
general, there is a correlation between the quality of overall
evidence and the strength of the recommendation. Thus, there
were 15 (40.5%) recommendations graded ‘1’ and 22 (59.5%)
graded ‘2.’ There were 2 (5.4%) recommendations graded ‘1A,’
8 (21.6%) were ‘1B,’ 1 (2.7%) were ‘1C,’ and 4 (10.8%) were
‘1D.’ There were 0 (0%) graded ‘2A,’ 1 (2.7%) were ‘2B,’ 13
(35.1%) were ‘2C,’ and 8 (21.6%) were ‘2D.’ There were 22
(37.3%) statements that were not graded.
Some argue that recommendations should not be made
when evidence is weak. However, clinicians still need to make
clinical decisions in their daily practice, and they often ask,
‘What do the experts do in this setting?’ We opted to give
guidance, rather than remain silent. These recommendations
are often rated with a low strength of recommendation and a
low strength of evidence, or were not graded. It is important
for the users of this guideline to be cognizant of this (see
Notice). In every case these recommendations are meant to
be a place for clinicians to start, not stop, their inquiries into
specific management questions pertinent to the patients they
see in daily practice.
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